Richard ''Buz'' Cooper Scholars 2015
The 2014 BBC grant also supported research by Drs. Tim Lucas and Arati Desai of Penn Medicine’s Department of Neurosurgery. Drs. Lucas and Desai use a multi-disciplinary approach to fighting some of the most difficult brain cancers, including glioblastoma. They used BBC funds to support preliminary studies on how to use microvesicles as a biomarker for tumor progression. This technique, they believe, provides a more precise and timely evaluation method than the traditional MRI. Drs. Lucas and Desai will continue to search for better diagnostic tools, which, in turn, will lead to better treatments and better outcomes for patients.
Cancer Research News At Penn Medicine's Abramson Cancer Center, physician-scientists work tirelessly to develop the latest personalized, innovative therapies that hold promise to one day turn the tide on brain cancer.
Read more from Penn Medicine's giving blog: Penn Medicine Blog
The funding supported research by Dr. Stephen Schuster, the Director of the Lymphoma Program at Penn Medicine's Abramson Cancer Center. Dr. Schuster’s research included participation in multi-center clinical trials that established new non-chemotherapeutic drugs to treat a variety of lymphomas, as well as chronic lymphocytic leukemia (CLL). These studies contributed to the FDA’s recent approval of two Kinase inhibitors, Ibrutinib and Idelalisib. In addition, Dr. Schuster’s team and patients served as a site for a clinical trial for a monoclonal antibody, Nivolumab, which proved remarkably effective in chemotherapy resistant Hodgkin lymphoma. The mechanism of action of this new antibody is based on a new understanding of cancer immunology. Specific kinase enzymes within tumor cells regulate their growth and survival. Blocking these enzymes increases treatment options for difficult-to-treat hematologic B-cell cancers, and offers options for patients who have resistance, or recurrence after standard therapies. Blocking the enzymes does not involve chemotherapy because the new antibody targets only the key enzymes in the cancer cells. Because the antibody is a non-chemotherapy agent, patients' quality of life while undergoing treatment is significantly enhanced. In the future, the antibody has the potential to be the first line of therapy, sparing patients from ever having to undergo chemotherapy.
The Breakthrough Bike Challenge Board of Directors presenting the proceeds from the 2014 bike ride